Psychopharmacology

, Volume 186, Issue 3, pp 481–485 | Cite as

3α,5α-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia

  • Charles D. Smith
  • David R. Wekstein
  • William R. Markesbery
  • Cheryl A. Frye
Original Investigation

Abstract

Rationale

A plasma biomarker for neurodegenerative disease is desirable because blood is relatively simple to obtain compared with other biological samples such as cerebrospinal fluid. Recent literature suggests that neurosteroid metabolism may be altered in Alzheimer's disease (AD).

Objectives

We sought to measure the plasma levels of seven steroids to assess their potential as biomarkers for dementia and AD. Methods: Steroids were measured using validated radioimmunoassay methods in AD (n=15), non-AD dementia (n=4), and control subjects (n=20). Demented subjects were in the mild-to-moderate stages of illness. Measurements were done blind to subject status in an independent laboratory.

Results

The notable finding was the significantly lower 5α-pregnan-3α-ol-20-one (3α,5α-THP) level in demented subjects compared with controls (25% decrease; p=0.004); 3α,5α-THP was the only one of the steroids demonstrating an effect of dementia.

Conclusion

Lowered 3α,5α-THP levels appear promising as a biomarker in dementia, but further work is needed to establish the sensitivity and specificity of these findings in AD.

Keywords

Neurosteroid Dementia Alzheimer's disease Biomarker Blood Plasma 3α,5α-THP Allopregnenolone 

References

  1. Baulieu EE, Robel P, Fellous A, Duchossoy Y, Fontaine-Lenoir V, David S (2004) MAPREG: toward a novel approach of neuroprotection and treatment of Alzheimer's disease. J Mol Neurosci 24:63–65PubMedCrossRefGoogle Scholar
  2. Dubrovsky BO (2005) Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 29:169–192CrossRefPubMedGoogle Scholar
  3. Finn DA, Gee KW (1994) The estrus cycle, sensitivity to convulsants and the anticonvulsant effect of a neuroactive steroid. J Pharmacol Exp Ther 271:164–170PubMedGoogle Scholar
  4. Frank C, Sagratella S (2000) Neuroprotective effects of allopregnenolone on hippocampal irreversible neurotoxicity in vitro. Prog Neuropsychopharmacol Biol Psychiatry 24:1117–1126CrossRefPubMedGoogle Scholar
  5. Frye CA, Lacey EH (2000) Progestins influence performance on cognitive tasks independent of changes in affective behavior. Psychobiology 8:550–563Google Scholar
  6. Frye CA, Scalise TJ, Bayon LE (1998) Finasteride blocks the reduction in ictal activity produced by exogenous estrous cyclicity. J Neuroendocrinol 10:291–296CrossRefPubMedGoogle Scholar
  7. Frye CA, Sturgis JD (1995) Neurosteroids affect spatial/reference, working, and long-term memory of female rats. Neurobiol Learn Mem 64:83–96CrossRefPubMedGoogle Scholar
  8. Herzog AG, Frye CA (2003) Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 53:390–391PubMedCrossRefGoogle Scholar
  9. Maurice T, Urani A, Phan VL, Romieu P (2001) The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev 37:116–132CrossRefPubMedGoogle Scholar
  10. Rhodes ME, McCormick CM, Frye CA (2004) 3alpha,5alpha-THP mediates progestins' effects to protect against adrenalectomy-induced cell death in the dentate gyrus of female and male rats. Pharmacol Biochem Behav 78:505–512CrossRefPubMedGoogle Scholar
  11. Schumacher M, Weill-Engerer S, Liere P, Robert F, Franklin RJ, Garcia-Segura LM, Lambert JJ, Mayo W, Melcangi RC, Parducz A, Suter U, Carelli C, Baulieu EE, Akwa Y (2003) Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog Neurobiol 71:3–29CrossRefPubMedGoogle Scholar
  12. Stoffel-Wagner B (2001) Neurosteroid metabolism in the human brain. Eur J Endocrinol 145:669–679CrossRefPubMedGoogle Scholar
  13. Twist SJ, Taylor GA, Weddell A, Weightman DR, Edwardson JA, Morris CM (2000) Brain oestradiol and testosterone levels in Alzheimer's disease. Neurosci Lett 286:1–4CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Charles D. Smith
    • 1
    • 2
    • 3
  • David R. Wekstein
    • 2
  • William R. Markesbery
    • 1
    • 2
  • Cheryl A. Frye
    • 3
  1. 1.Department of NeurologyUniversity of Kentucky Medical CenterLexingtonUSA
  2. 2.Sanders–Brown Center on AgingUniversity of Kentucky Medical CenterLexingtonUSA
  3. 3.Department of Psychology, Biology and Center for Neuroscience ResearchThe University at Albany-SUNYAlbanyUSA

Personalised recommendations